MedTrace Logo

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

NCT02162862 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2017-09-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if either a targeted type of talk therapy (Phase I) or medication, Wellbutrin, (Phase II) improve sleep disturbance and/or fatigue in individuals with Inflammatory Bowel Disease (IBD).

Conditions

Interventions

BEHAVIORAL

Behavioral Counseling

DRUG

bupropion-SR

Sponsors & Collaborators

  • Crohn's and Colitis Foundation

    collaborator OTHER

  • Eva Szigethy

    lead OTHER

Principal Investigators

  • Eva Szigethy, MD, PhD · University of Pittsburgh

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
15 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162862 on ClinicalTrials.gov